Pharming Group reports third quarter 2024 financial results and provides business update
Financial updatesPharming Group N.V. presents its preliminary, unaudited financial report for the three months ended September 30, 2024.
Pharming Group to report third quarter 2024 financial results on October 24
Financial updatesPharming Group N.V. confirms it will report its preliminary (unaudited) third quarter 2024 financial results, for the period ended September 30, on Thursday, October 24, 2024.
Pharming Group announces start of Phase II clinical trial of leniolisib for primary immunodeficiencies (PIDs) with immune dysregulation
Clinical trials
Pharming announces marketing authorization in the U.K. for Joenja® (leniolisib)
Operational updatesFor media and investors only
Pharming Group to participate in September investor conferences
Conference attendancePharming Group N.V. announces that Pharming’s management will participate in the following investor conferences in the U.S. in the month of September:
Pharming Group reports second quarter and first half 2024 financial results and provides business update
Financial updatesPharming Group N.V. presents its preliminary (unaudited) financial report for the second quarter and first half year ended June 30, 2024.
Pharming Group to report second quarter and first half 2024 financial results on August 1
Financial updatesPharming Group N.V. confirms it will report its preliminary (unaudited) second quarter and first half 2024 financial results, for the period ended June 30, on Thursday, August 1, 2024.
Pharming Group to participate in June investor conferences
Conference attendancePharming Group N.V. announces that Pharming’s management will participate in the following investor conferences in the month of June:
Pharming Group provides update on ongoing regulatory review of leniolisib for the treatment of APDS in the European Union
Corporate updatesPharming Group N.V. announces today an update on the ongoing review of its Marketing Authorisation Application (MAA) for leniolisib for the treatment of adult and pediatric patients 12 years of age and older with activated phosphoinositide 3-kinase delta syndrome (APDS) by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).
Pharming Group reports on results of the 2024 Annual General Meeting of Shareholders
Corporate updatesPharming Group N.V. announces that at its Annual General Meeting of Shareholders (AGM) held today, all proposals were approved.